In vitro comparison of acyclovir, ganciclovir and cidofovir against equid alphaherpesvirus 3 and evaluation of their efficacy against six field isolates = Comparación in vitro de aciclovir, ganciclovir y cidofovir contra alfa-herpesvirus equino 3 y evaluación de la eficacia de los mismos frente a 6 aislamientos de campo del virus

Equid alphaherpesvirus 3 (EHV3) is the etiological agent of equine coital exanthema (ECE), which is a venereal, highly contagious disease, characterized by the formation of papules, vesicles, pustules and ulcers on the external genitalia of mares and stallions. EHV3 remains in a latent state after a successful infection and there are latently infected animals in which the virus is reactivated and generally re-excreted subclinically. There are no available vaccines for this condition and prevention is based on the clinical examination of mares prior to mating, which allows to segregate those showing clinical signs. As this approach does not eliminate the risk of contagion in stallions from subclinically infected mares, there is a need for a specific EHV3 treatment. Nowadays, there exist various antiviral compounds of proven effectiveness for other alphaherpesviruses affecting humans and animals. The aim of the present study was to compare the efficacy of three antiviral compounds, acyclovir, ganciclovir and cidofovir against EHV3 in vitro, and to assess their efficacy against six EHV3 Argentinian field isolates. To determine the efficacy of these compounds in vitro, three parameters were analyzed: reduction of plaque number, reduction of plaque size and reduction of viral production. Additionally, the effectiveness of the three compounds at an optimum concentration previously determined in this study was investigated for the EHV3 field isolates. Based on our results, ganciclovir was the most potent antiviral compound to reduce EHV3 replication in vitro and may thus be a valuable candidate for treatment and prevention of ECE in mares and stallions.

Saved in:
Bibliographic Details
Main Authors: Vissani, Maria Aldana, Zabal, Osvaldo Alfredo, Tordoya, Maria Silvia, Parreño, Viviana, Thiry, Etienne, Barrandeguy, Maria Edith
Format: info:ar-repo/semantics/artículo biblioteca
Language:eng
Published: Asociación Argentina de Microbiología 2018
Subjects:Herpes Virus Equino, Exantema Coital, Viricidas, Medicamentos, Experimentación In Vitro, Equine Herpesvirus, Coital Exanthema, Antiviral Agents, Drugs, In Vitro Experimentation, Alfa-herpesvirus Equino 3, Equid Alphaherpesvirus 3,
Online Access:http://hdl.handle.net/20.500.12123/4449
https://www.sciencedirect.com/science/article/pii/S0325754118300051
https://doi.org/10.1016/j.ram.2018.01.003
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:localhost:20.500.12123-4449
record_format koha
institution INTA AR
collection DSpace
country Argentina
countrycode AR
component Bibliográfico
access En linea
databasecode dig-inta-ar
tag biblioteca
region America del Sur
libraryname Biblioteca Central del INTA Argentina
language eng
topic Herpes Virus Equino
Exantema Coital
Viricidas
Medicamentos
Experimentación In Vitro
Equine Herpesvirus
Coital Exanthema
Antiviral Agents
Drugs
In Vitro Experimentation
Alfa-herpesvirus Equino 3
Equid Alphaherpesvirus 3
Herpes Virus Equino
Exantema Coital
Viricidas
Medicamentos
Experimentación In Vitro
Equine Herpesvirus
Coital Exanthema
Antiviral Agents
Drugs
In Vitro Experimentation
Alfa-herpesvirus Equino 3
Equid Alphaherpesvirus 3
spellingShingle Herpes Virus Equino
Exantema Coital
Viricidas
Medicamentos
Experimentación In Vitro
Equine Herpesvirus
Coital Exanthema
Antiviral Agents
Drugs
In Vitro Experimentation
Alfa-herpesvirus Equino 3
Equid Alphaherpesvirus 3
Herpes Virus Equino
Exantema Coital
Viricidas
Medicamentos
Experimentación In Vitro
Equine Herpesvirus
Coital Exanthema
Antiviral Agents
Drugs
In Vitro Experimentation
Alfa-herpesvirus Equino 3
Equid Alphaherpesvirus 3
Vissani, Maria Aldana
Zabal, Osvaldo Alfredo
Tordoya, Maria Silvia
Parreño, Viviana
Thiry, Etienne
Barrandeguy, Maria Edith
In vitro comparison of acyclovir, ganciclovir and cidofovir against equid alphaherpesvirus 3 and evaluation of their efficacy against six field isolates = Comparación in vitro de aciclovir, ganciclovir y cidofovir contra alfa-herpesvirus equino 3 y evaluación de la eficacia de los mismos frente a 6 aislamientos de campo del virus
description Equid alphaherpesvirus 3 (EHV3) is the etiological agent of equine coital exanthema (ECE), which is a venereal, highly contagious disease, characterized by the formation of papules, vesicles, pustules and ulcers on the external genitalia of mares and stallions. EHV3 remains in a latent state after a successful infection and there are latently infected animals in which the virus is reactivated and generally re-excreted subclinically. There are no available vaccines for this condition and prevention is based on the clinical examination of mares prior to mating, which allows to segregate those showing clinical signs. As this approach does not eliminate the risk of contagion in stallions from subclinically infected mares, there is a need for a specific EHV3 treatment. Nowadays, there exist various antiviral compounds of proven effectiveness for other alphaherpesviruses affecting humans and animals. The aim of the present study was to compare the efficacy of three antiviral compounds, acyclovir, ganciclovir and cidofovir against EHV3 in vitro, and to assess their efficacy against six EHV3 Argentinian field isolates. To determine the efficacy of these compounds in vitro, three parameters were analyzed: reduction of plaque number, reduction of plaque size and reduction of viral production. Additionally, the effectiveness of the three compounds at an optimum concentration previously determined in this study was investigated for the EHV3 field isolates. Based on our results, ganciclovir was the most potent antiviral compound to reduce EHV3 replication in vitro and may thus be a valuable candidate for treatment and prevention of ECE in mares and stallions.
format info:ar-repo/semantics/artículo
topic_facet Herpes Virus Equino
Exantema Coital
Viricidas
Medicamentos
Experimentación In Vitro
Equine Herpesvirus
Coital Exanthema
Antiviral Agents
Drugs
In Vitro Experimentation
Alfa-herpesvirus Equino 3
Equid Alphaherpesvirus 3
author Vissani, Maria Aldana
Zabal, Osvaldo Alfredo
Tordoya, Maria Silvia
Parreño, Viviana
Thiry, Etienne
Barrandeguy, Maria Edith
author_facet Vissani, Maria Aldana
Zabal, Osvaldo Alfredo
Tordoya, Maria Silvia
Parreño, Viviana
Thiry, Etienne
Barrandeguy, Maria Edith
author_sort Vissani, Maria Aldana
title In vitro comparison of acyclovir, ganciclovir and cidofovir against equid alphaherpesvirus 3 and evaluation of their efficacy against six field isolates = Comparación in vitro de aciclovir, ganciclovir y cidofovir contra alfa-herpesvirus equino 3 y evaluación de la eficacia de los mismos frente a 6 aislamientos de campo del virus
title_short In vitro comparison of acyclovir, ganciclovir and cidofovir against equid alphaherpesvirus 3 and evaluation of their efficacy against six field isolates = Comparación in vitro de aciclovir, ganciclovir y cidofovir contra alfa-herpesvirus equino 3 y evaluación de la eficacia de los mismos frente a 6 aislamientos de campo del virus
title_full In vitro comparison of acyclovir, ganciclovir and cidofovir against equid alphaherpesvirus 3 and evaluation of their efficacy against six field isolates = Comparación in vitro de aciclovir, ganciclovir y cidofovir contra alfa-herpesvirus equino 3 y evaluación de la eficacia de los mismos frente a 6 aislamientos de campo del virus
title_fullStr In vitro comparison of acyclovir, ganciclovir and cidofovir against equid alphaherpesvirus 3 and evaluation of their efficacy against six field isolates = Comparación in vitro de aciclovir, ganciclovir y cidofovir contra alfa-herpesvirus equino 3 y evaluación de la eficacia de los mismos frente a 6 aislamientos de campo del virus
title_full_unstemmed In vitro comparison of acyclovir, ganciclovir and cidofovir against equid alphaherpesvirus 3 and evaluation of their efficacy against six field isolates = Comparación in vitro de aciclovir, ganciclovir y cidofovir contra alfa-herpesvirus equino 3 y evaluación de la eficacia de los mismos frente a 6 aislamientos de campo del virus
title_sort in vitro comparison of acyclovir, ganciclovir and cidofovir against equid alphaherpesvirus 3 and evaluation of their efficacy against six field isolates = comparación in vitro de aciclovir, ganciclovir y cidofovir contra alfa-herpesvirus equino 3 y evaluación de la eficacia de los mismos frente a 6 aislamientos de campo del virus
publisher Asociación Argentina de Microbiología
publishDate 2018
url http://hdl.handle.net/20.500.12123/4449
https://www.sciencedirect.com/science/article/pii/S0325754118300051
https://doi.org/10.1016/j.ram.2018.01.003
work_keys_str_mv AT vissanimariaaldana invitrocomparisonofacyclovirganciclovirandcidofoviragainstequidalphaherpesvirus3andevaluationoftheirefficacyagainstsixfieldisolatescomparacioninvitrodeaciclovirganciclovirycidofovircontraalfaherpesvirusequino3yevaluaciondelaeficaciadelosmismosfrentea6aisl
AT zabalosvaldoalfredo invitrocomparisonofacyclovirganciclovirandcidofoviragainstequidalphaherpesvirus3andevaluationoftheirefficacyagainstsixfieldisolatescomparacioninvitrodeaciclovirganciclovirycidofovircontraalfaherpesvirusequino3yevaluaciondelaeficaciadelosmismosfrentea6aisl
AT tordoyamariasilvia invitrocomparisonofacyclovirganciclovirandcidofoviragainstequidalphaherpesvirus3andevaluationoftheirefficacyagainstsixfieldisolatescomparacioninvitrodeaciclovirganciclovirycidofovircontraalfaherpesvirusequino3yevaluaciondelaeficaciadelosmismosfrentea6aisl
AT parrenoviviana invitrocomparisonofacyclovirganciclovirandcidofoviragainstequidalphaherpesvirus3andevaluationoftheirefficacyagainstsixfieldisolatescomparacioninvitrodeaciclovirganciclovirycidofovircontraalfaherpesvirusequino3yevaluaciondelaeficaciadelosmismosfrentea6aisl
AT thiryetienne invitrocomparisonofacyclovirganciclovirandcidofoviragainstequidalphaherpesvirus3andevaluationoftheirefficacyagainstsixfieldisolatescomparacioninvitrodeaciclovirganciclovirycidofovircontraalfaherpesvirusequino3yevaluaciondelaeficaciadelosmismosfrentea6aisl
AT barrandeguymariaedith invitrocomparisonofacyclovirganciclovirandcidofoviragainstequidalphaherpesvirus3andevaluationoftheirefficacyagainstsixfieldisolatescomparacioninvitrodeaciclovirganciclovirycidofovircontraalfaherpesvirusequino3yevaluaciondelaeficaciadelosmismosfrentea6aisl
_version_ 1763176996473405441
spelling oai:localhost:20.500.12123-44492023-04-12T16:07:56Z In vitro comparison of acyclovir, ganciclovir and cidofovir against equid alphaherpesvirus 3 and evaluation of their efficacy against six field isolates = Comparación in vitro de aciclovir, ganciclovir y cidofovir contra alfa-herpesvirus equino 3 y evaluación de la eficacia de los mismos frente a 6 aislamientos de campo del virus Vissani, Maria Aldana Zabal, Osvaldo Alfredo Tordoya, Maria Silvia Parreño, Viviana Thiry, Etienne Barrandeguy, Maria Edith Herpes Virus Equino Exantema Coital Viricidas Medicamentos Experimentación In Vitro Equine Herpesvirus Coital Exanthema Antiviral Agents Drugs In Vitro Experimentation Alfa-herpesvirus Equino 3 Equid Alphaherpesvirus 3 Equid alphaherpesvirus 3 (EHV3) is the etiological agent of equine coital exanthema (ECE), which is a venereal, highly contagious disease, characterized by the formation of papules, vesicles, pustules and ulcers on the external genitalia of mares and stallions. EHV3 remains in a latent state after a successful infection and there are latently infected animals in which the virus is reactivated and generally re-excreted subclinically. There are no available vaccines for this condition and prevention is based on the clinical examination of mares prior to mating, which allows to segregate those showing clinical signs. As this approach does not eliminate the risk of contagion in stallions from subclinically infected mares, there is a need for a specific EHV3 treatment. Nowadays, there exist various antiviral compounds of proven effectiveness for other alphaherpesviruses affecting humans and animals. The aim of the present study was to compare the efficacy of three antiviral compounds, acyclovir, ganciclovir and cidofovir against EHV3 in vitro, and to assess their efficacy against six EHV3 Argentinian field isolates. To determine the efficacy of these compounds in vitro, three parameters were analyzed: reduction of plaque number, reduction of plaque size and reduction of viral production. Additionally, the effectiveness of the three compounds at an optimum concentration previously determined in this study was investigated for the EHV3 field isolates. Based on our results, ganciclovir was the most potent antiviral compound to reduce EHV3 replication in vitro and may thus be a valuable candidate for treatment and prevention of ECE in mares and stallions. El alfa-herpesvirus equino 3 (EHV3) es el agente etiológico del exantema coital equino (ECE), enfermedad venérea, altamente contagiosa y caracterizada por la aparición de pápulas, vesículas, pústulas y úlceras en los genitales externos de yeguas y padrillos. Luego de la primo-infección, el EHV3 se mantiene en el animal en un estado de latencia a partir del cual puede reactivar y excretarse, generalmente de manera subclínica. No existen vacunas, por lo que la prevención se basa en la detección de las lesiones clínicas previo al servicio, y la segregación de estos animales. Sin embargo, este abordaje no previene la infección del padrillo por parte de yeguas que excretan el virus de manera subclínica, y por lo tanto existe la necesidad de un tratamiento específico contra el EHV3. En la actualidad, existen varios compuestos antivirales de probada eficacia contra herpesvirus humanos y veterinarios. El objetivo de este trabajo es comparar la eficacia de 3 compuestos antivirales, aciclovir, ganciclovir y cidofovir, contra EHV3 in vitro, y evaluar la eficacia de los mismos contra 6 cepas de campo argentinas de EHV3. Para determinar la eficacia de los compuestos in vitro se evaluaron 3 parámetros: reducción del número de placas de lisis, reducción del tamaño de placas de lisis y reducción de la producción de virus. Adicionalmente, la efectividad de los compuestos en una concentración óptima, previamente determinada en este estudio, fue determinada para 6 cepas de campo argentinas de EHV3. De acuerdo con los resultados obtenidos, ganciclovir fue el compuesto más potente en reducir la replicación del EHV3 in vitro, y por lo tanto podría considerarse un potencial candidato para el tratamiento y la prevención del ECE en yeguas y padrillos. Instituto de Virología Fil: Vissani, Aldana. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina Fil: Zabal, Osvaldo Alfredo. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Universidad del Salvador. Escuela de Veterinaria. Cátedra de Enfermedades Infecciosas; Argentina Fil: Tordoya, Maria Silvia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina Fil: Parreño, Viviana. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina Fil: Thiry, Etienne. University of Liege. Faculty of Veterinary Medicine. Veterinary Virology and Animal Viral Diseases and UREAR. Department of Infectious and Parasitic Diseases; Bélgica Fil: Barrandeguy, Maria Edith. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Universidad del Salvador. Escuela de Veterinaria. Cátedra de Enfermedades Infecciosas; Argentina 2019-02-15T14:22:26Z 2019-02-15T14:22:26Z 2018 info:ar-repo/semantics/artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/20.500.12123/4449 https://www.sciencedirect.com/science/article/pii/S0325754118300051 0325-7541 https://doi.org/10.1016/j.ram.2018.01.003 eng info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) application/pdf Asociación Argentina de Microbiología Revista argentina de microbiología 50 (4) : 380-390. (October–December 2018)